CA2325358A1 - 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b - Google Patents

7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b Download PDF

Info

Publication number
CA2325358A1
CA2325358A1 CA002325358A CA2325358A CA2325358A1 CA 2325358 A1 CA2325358 A1 CA 2325358A1 CA 002325358 A CA002325358 A CA 002325358A CA 2325358 A CA2325358 A CA 2325358A CA 2325358 A1 CA2325358 A1 CA 2325358A1
Authority
CA
Canada
Prior art keywords
apolipoprotein
secretion
methods
inhibiting
quinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002325358A
Other languages
French (fr)
Other versions
CA2325358C (en
Inventor
Peter Bertinato
Ernest Seiichi Hamanaka
Roger Benjamin Ruggeri
Douglas Paul Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CA2325358A1 publication Critical patent/CA2325358A1/en
Application granted granted Critical
Publication of CA2325358C publication Critical patent/CA2325358C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

This invention relates to compounds of Formula I
(see formula I) that inhibit the secretion of apolipoprotein B, to pharmaceutical compositions comprising the compounds, and to methods of treating and/or preventing atherosclerosis, obesity, diabetes, hyperlipidemia, hyperliproproteinemia, hypercholesterolemia, hypertriglyceridemia, hypoalphalipoproteinemia, pancreatitis, myocardial infarction, stroke, restenosis, or Syndrome X. This invention also relates to methods of reducing the secretion of apolipoprotein B and/or inhibiting microsomal triglyceride transfer protein.
CA002325358A 1999-11-10 2000-11-08 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b Expired - Fee Related CA2325358C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16480399P 1999-11-10 1999-11-10
US60/164,803 1999-11-10
US22495600P 2000-08-11 2000-08-11
US60/224,956 2000-08-11

Publications (2)

Publication Number Publication Date
CA2325358A1 true CA2325358A1 (en) 2001-05-10
CA2325358C CA2325358C (en) 2005-08-02

Family

ID=26860863

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002325358A Expired - Fee Related CA2325358C (en) 1999-11-10 2000-11-08 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b

Country Status (6)

Country Link
US (2) US6369075B1 (en)
EP (1) EP1099701A1 (en)
JP (1) JP3524868B2 (en)
BR (1) BR0005322A (en)
CA (1) CA2325358C (en)
MX (1) MXPA00011105A (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
US7041691B1 (en) * 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6678740B1 (en) * 2000-01-14 2004-01-13 Terayon Communication Systems, Inc. Process carried out by a gateway in a home network to receive video-on-demand and other requested programs and services
US20020059637A1 (en) * 2000-01-14 2002-05-16 Rakib Selim Shlomo Home gateway for video and data distribution from various types of headend facilities and including digital video recording functions
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
US20030171399A1 (en) * 2000-06-28 2003-09-11 Tularik Inc. Quinolinyl and benzothiazolyl modulators
DE10033337A1 (en) * 2000-07-08 2002-01-17 Boehringer Ingelheim Pharma Biphenylcarboxamides, their preparation and their use as medicaments
AU2001277727A1 (en) * 2000-08-10 2002-02-25 Tanabe Seiyaku Co., Ltd. Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof
US6417367B1 (en) * 2000-08-11 2002-07-09 Pfizer Inc. Methods of making quinoline amides
SI1404653T1 (en) * 2001-06-28 2008-12-31 Pfizer Prod Inc Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
CA2464981A1 (en) * 2001-10-25 2003-05-01 Takeda Chemical Industries, Ltd. Quinoline compound
EP1465613A2 (en) * 2002-01-10 2004-10-13 Boehringer Ingelheim Pharma GmbH & Co. KG Combination of mtp inhibitors or apob secretion inhibitors with fibrates for use as drugs
DE60325025D1 (en) * 2002-02-15 2009-01-15 Glaxo Group Ltd MODULATORS OF THE VANILLOID RECEPTOR
KR20040095239A (en) * 2002-02-27 2004-11-12 화이자 프로덕츠 인코포레이티드 Acc inhibitors
EP1479666A4 (en) * 2002-02-28 2010-10-13 Japan Tobacco Inc Ester compound and medicinal use thereof
AU2003262947A1 (en) * 2002-08-30 2004-03-19 Pharmacia And Upjohn Company Method of preventing or treating atherosclerosis or restenosis
WO2004019933A1 (en) * 2002-08-30 2004-03-11 Pharmacia & Upjohn Company Method of preventing or treating atherosclerosis or restenosis
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
CA2505604A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
AU2003286347A1 (en) * 2002-12-20 2004-07-14 Pfizer Products Inc. Microsomal triglyceride transfer protein inhibitors
JP2006519229A (en) * 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ Regulation of food intake and glucose production by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
KR101106631B1 (en) 2003-02-13 2012-01-20 웰스태트 테러퓨틱스 코포레이션 Compounds for the Treatment of Metabolic Disorders
EP1636592B1 (en) * 2003-06-19 2012-12-19 Merck Serono SA Use of prion conversion modulating agents
KR20060058092A (en) 2003-07-23 2006-05-29 신타 파마슈티칼스 코프. Compounds for inflammation and immune-related uses
CA2530352A1 (en) * 2003-07-24 2005-02-03 Astellas Pharma Inc. Quinolone derivative or salt thereof
EP1669345A4 (en) 2003-08-29 2008-02-20 Japan Tobacco Inc Ester derivative and medicinal use thereof
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
GB0323348D0 (en) * 2003-10-06 2003-11-05 Cambridge Theranostics Ltd Methods and means for modulating lipid metabolism
WO2005032493A2 (en) 2003-10-07 2005-04-14 Renovis, Inc. Amide compounds as ion channel ligands and uses thereof
GB2413129A (en) * 2003-10-07 2005-10-19 Renovis Inc Aromatic amide compounds as ion channel ligands and uses thereof
CA2555133A1 (en) 2004-02-04 2005-09-01 Pfizer Products Inc. Substituted quinoline compounds
JP2007527918A (en) * 2004-03-08 2007-10-04 アムジェン インコーポレイテッド Therapeutic modulation of PPAR gamma activity
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP1806149A4 (en) * 2004-10-25 2012-12-05 Japan Tobacco Inc Solid medicinal preparation improved in solubility and stability and process for producing the same
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
US20070026079A1 (en) * 2005-02-14 2007-02-01 Louis Herlands Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels
FR2884831B1 (en) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
DK2046787T3 (en) 2006-08-01 2011-07-18 Glaxo Group Ltd Pyrazolo [3,4-B] pyridine compounds, and their use as PDE4 inhibitors
WO2008100423A1 (en) * 2007-02-09 2008-08-21 Sirtris Pharmaceuticals, Inc. Gut microsomal triglyceride transport protein inhibitors
CA2678575C (en) * 2007-02-16 2013-10-08 Emisphere Technologies, Inc. Compounds having a cyclic moiety and compositions for delivering active agents
PL2225261T3 (en) 2007-12-03 2016-09-30 Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism
EP2258676B1 (en) * 2008-03-28 2016-02-17 Takeda Pharmaceutical Company Limited Stable vinamidinium salt and nitrogen-containing heterocyclic ring synthesis using the same
RU2624506C2 (en) 2009-04-29 2017-07-04 АМАРИН КОРПОРЕЙШН ПиЭлСи Pharmaceutical compositions containing epa and cardiovascular agents and their application methods
US8778941B2 (en) 2011-06-24 2014-07-15 Amgen Inc. TRPM8 antagonists and their use in treatments
CA2839699A1 (en) 2011-06-24 2012-12-27 Amgen Inc. Trpm8 antagonists and their use in treatments
US9309237B2 (en) 2011-09-06 2016-04-12 New York Blood Center, Inc. HIV inhibitors
US8952009B2 (en) 2012-08-06 2015-02-10 Amgen Inc. Chroman derivatives as TRPM8 inhibitors
EP3194030B1 (en) 2014-09-19 2019-11-06 New York Blood Center, Inc. Substituted phenylpyrrolecarboxamides with therapeutic activity in hiv
GB2589910B (en) * 2019-12-12 2021-12-01 Henkel IP & Holding GmbH Process for preparing cyanoacetates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919795A (en) * 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
CN1209803A (en) 1996-01-16 1999-03-03 布里斯托尔-迈尔斯斯奎布公司 Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method therefor
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method

Also Published As

Publication number Publication date
JP2001139555A (en) 2001-05-22
US6369075B1 (en) 2002-04-09
US20020132806A1 (en) 2002-09-19
EP1099701A1 (en) 2001-05-16
CA2325358C (en) 2005-08-02
MXPA00011105A (en) 2002-05-23
US6713489B2 (en) 2004-03-30
JP3524868B2 (en) 2004-05-10
BR0005322A (en) 2001-07-17

Similar Documents

Publication Publication Date Title
CA2325358A1 (en) 7-¬(4'-trifluoromethyl-biphenyl-2-carbonyl)amino|-quinoline-3-carboxylic acid amides, and methods of inhibiting the secretion of apolipoprotein b
BG103264A (en) Substituted n-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
WO2001022953A3 (en) Use of retigabin for treating neuropathic pain
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
CA2261848A1 (en) Cell adhesion inhibitors
EE04060B1 (en) Heterocyclic compounds for inhibiting gastric acid secretion, process for their preparation and pharmaceutical compositions
BR9813264A (en) fatty acids, surfactant systems and consumer products based on them
IL135319A0 (en) Apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
IL160769A0 (en) Heterocyclic compounds and pharmaceutical compositions containing the same
NZ237023A (en) 17beta-substituted-4-aza-5alpha-androstan-3-ones and pharmaceutical compositions
WO2001097810A3 (en) Use of therapeutic benzamide derivatives
PL332509A1 (en) Beta-sulphonyl-hydroxamic acids as inhibitors of intercellular substance metaloproteinases
PL351618A1 (en) Pyridine-2,3-dicarboxylic diamides
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
JO2298B1 (en) 2-(3.5-bis-trifluoromethyl-phenyl)- n-methyl-n-(6-morpholin-4-yl-4-o-tolyl -pyridin-3-yl) -isobutyramide
IL117209A (en) 1-aryl-2-acylamino-ethane compounds and pharmaceutical compositions containing them
CA2347117A1 (en) Methods for inhibiting diabetic complications
AU2001236485A1 (en) Novel orthogonally protected amino acid chelators for biomedical applications
WO2000053182A3 (en) 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis
CA2356157A1 (en) Combinations of cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
IL111395A (en) 5-(Arylisoxazole-4-yl)-substituted 2-amino carboxylic acid compounds and pharmaceutical compositions containing them
AU4568400A (en) Sphingomyelinase inhibitor
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
HUP0004461A3 (en) Use of apolipoprotein b secretion/microsomal triglyceride transfer protein inhibitor for producing pharmaceutical composition and these pharmaceutical compositions
IL125660A0 (en) Pharmaceutical composition comprising 2-(3,4-dimethoxycinnamoyl)-aminobenzoic acid for the aminobenzoic acid for the treatment or prevention of restenosis and its manufacture

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed